Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Expert Review of Hematology|July 28, 2018
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?Simon Rule, Robert W ChenClinical Advances in Hematology & Oncology : H&O|October 3, 2015
Managing Risk in Hodgkin LymphomaJames O Armitage, Robert W Chen, Craig H Moskowitz, et al.Comparative Medicine|June 24, 2014
Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma modelDeepti Chadalavada, Trinka W Adamson, John C Burnett, et al.Blood|May 17, 2008
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphomaRobert W Chen, Lynne T Bemis, Carol M Amato, et al.Leukemia & Lymphoma|July 13, 2011
Small interfering RNAs targeting cyclin D1 and cyclin D2 enhance the cytotoxicity of chemotherapeutic agents in mantle cell lymphoma cell linesKatrin Tiemann, Jessica V Alluin, Anja Honegger, et al.Blood Advances|October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphomaCraig A Portell, Nolan A Wages, Brad S Kahl, et al.Oncotarget|October 8, 2016
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphomaAtish Mohanty, Natalie Sandoval, Manasi Das, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.Blood|December 12, 2018
Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphomaAtish Mohanty, Natalie Sandoval, An Phan, et al.Pageof 2